Literature DB >> 25937768

Review: the role of hyperthermia in treating pancreatic tumors.

Martin Roesch1, Boris Mueller-Huebenthal2.   

Abstract

There is only marginal improvement in outcome of treating pancreatic cancer in the last two decades. Time to open up and have a fresh look at complementary adjuvant treatment options. Hyperthermia may be one such option. Hyperthermic intraperitoneal chemotherapy (HIPEC) predominantly as a intrasurgical procedure has already proved its justification. Non-invasive loco regional hyperthermia as complement to either chemo or radiation has not yet reached a comparable status of evidence. However the potential to eventually grow into such evidence is already clearly observable. This review presents the various methodologies available for hyperthermia, covers the initial clinical data that has been published and gives an outlook to what can be expected in the next 2-3 years to come. Hyperthermia has the potential to significantly prolong life expectancies and this while maintaining a satisfying quality of life!

Entities:  

Keywords:  Adjuvant heat treatment; Hyperthermia; Palliative pain reduction; Pancreatic cancer

Year:  2014        PMID: 25937768      PMCID: PMC4412860          DOI: 10.1007/s13193-014-0316-5

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  29 in total

1.  [Efficacy of whole body gamma-knife radiotherapy combined with thermochemotherapy on locally advanced pancreatic cancer].

Authors:  Li-Ping Zhang; Qing Nie; Jing-Bo Kang; Bin Wang; Chang-Lan Cai; Jian-Guo Li; Wen-Jie Qi
Journal:  Ai Zheng       Date:  2008-11

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

Review 3.  Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Deng-Hai Mi; Zheng Li; Ke-Hu Yang; Nong Cao; Anne Lethaby; Jin-Hui Tian; Nancy Santesso; Bin Ma; Yao-Long Chen; Ya-Li Liu
Journal:  Int J Hyperthermia       Date:  2013       Impact factor: 3.914

4.  Intraoperative hyperthermia in conjunction with multi-schedule chemotherapy (pre-, intra- and post-operative), by-pass surgery, and post-operative radiotherapy for the management of unresectable pancreatic adenocarcinoma.

Authors:  V E Kouloulias; J R Kouvaris; K S Nikita; B C Golematis; N K Uzunoglu; K Mystakidou; C Papavasiliou; L Vlahos
Journal:  Int J Hyperthermia       Date:  2002 May-Jun       Impact factor: 3.914

5.  Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer.

Authors:  Katharina Elisabeth Tschoep-Lechner; Valeria Milani; Frank Berger; Nelli Dieterle; Sultan Abdel-Rahman; Christoph Salat; Rolf-Dieter Issels
Journal:  Int J Hyperthermia       Date:  2012-12-17       Impact factor: 3.914

6.  Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol.

Authors:  Joan M C Bull; Glenna L Scott; Frederick R Strebel; Verne L Nagle; Dwight Oliver; Michael Redwine; R Wanda Rowe; Chul W Ahn; Steven M Koch
Journal:  Int J Hyperthermia       Date:  2008-12       Impact factor: 3.914

7.  Effect of hyperthermia combined with gemcitabine on apoptotic cell death in cultured human pancreatic cancer cell lines.

Authors:  Satoko Adachi; Satoshi Kokura; Tetsuya Okayama; Takeshi Ishikawa; Tomohisa Takagi; Osamu Handa; Yuji Naito; Toshikazu Yoshikawa
Journal:  Int J Hyperthermia       Date:  2009-05       Impact factor: 3.914

Review 8.  Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.

Authors:  Lionel Apetoh; Antoine Tesniere; François Ghiringhelli; Guido Kroemer; Laurence Zitvogel
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

9.  Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer.

Authors:  Hong Zhao; Guowang Yang; Daoyuan Wang; Xiangrong Yu; Yu Zhang; Junqiu Zhu; Yongle Ji; Baoliang Zhong; Wenshuo Zhao; Zhong Yang; Fahad Aziz
Journal:  Anticancer Drugs       Date:  2010-04       Impact factor: 2.248

10.  High intensity focused ultrasound treatment for patients with advanced pancreatic cancer: a preliminary dosimetric analysis.

Authors:  Kun Wang; Lianyu Chen; Zhiqiang Meng; Junhua Lin; Zhenhua Zhou; Peng Wang; Zhen Chen
Journal:  Int J Hyperthermia       Date:  2012-09-04       Impact factor: 3.914

View more
  2 in total

Review 1.  Gemcitabine Combination Nano Therapies for Pancreatic Cancer.

Authors:  Kamalika Samanta; Saini Setua; Sonam Kumari; Meena Jaggi; Murali M Yallapu; Subhash C Chauhan
Journal:  Pharmaceutics       Date:  2019-11-04       Impact factor: 6.321

2.  Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group.

Authors:  Sohei Satoi; Naminatsu Takahara; Tsutomu Fujii; Hiroyuki Isayama; Suguru Yamada; Yasushi Tsuji; Hideyo Miyato; Hironori Yamaguchi; Tomohisa Yamamoto; Daisuke Hashimoto; So Yamaki; Yousuke Nakai; Kei Saito; Hayato Baba; Toru Watanabe; Shigeto Ishii; Masamichi Hayashi; Keisuke Kurimoto; Hideaki Shimada; Joji Kitayama
Journal:  J Hepatobiliary Pancreat Sci       Date:  2022-01-07       Impact factor: 3.149

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.